Glycoprotein YKL-40 : A potential biomarker of disease activity in rheumatoid arthritis during intensive treatment with csDMARDs and infliximab. Evidence from the randomised controlled NEO-RACo trial

Show full item record



Permalink

http://hdl.handle.net/10138/224337

Citation

Vaananen , T , Vuolteenaho , K , Kautiainen , H , Nieminen , R , Mottonen , T , Hannonen , P , Korpela , M , Kauppi , M J , Laiho , K , Kaipiainen-Seppanen , O , Luosujarvi , R , Uusitalo , T , Uutela , T , Leirisalo-Repo , M , Moilanen , E & NEO-RACo Study Grp 2017 , ' Glycoprotein YKL-40 : A potential biomarker of disease activity in rheumatoid arthritis during intensive treatment with csDMARDs and infliximab. Evidence from the randomised controlled NEO-RACo trial ' , PLoS One , vol. 12 , no. 8 , 0183294 . https://doi.org/10.1371/journal.pone.0183294

Title: Glycoprotein YKL-40 : A potential biomarker of disease activity in rheumatoid arthritis during intensive treatment with csDMARDs and infliximab. Evidence from the randomised controlled NEO-RACo trial
Author: Vaananen, Tuija; Vuolteenaho, Katriina; Kautiainen, Hannu; Nieminen, Riina; Mottonen, Timo; Hannonen, Pekka; Korpela, Markku; Kauppi, Markku J.; Laiho, Kari; Kaipiainen-Seppanen, Oili; Luosujarvi, Riitta; Uusitalo, Tea; Uutela, Toini; Leirisalo-Repo, Marjatta; Moilanen, Eeva; NEO-RACo Study Grp
Contributor: University of Helsinki, Department of General Practice and Primary Health Care
University of Helsinki, HYKS erva
University of Helsinki, HYKS erva
University of Helsinki, University of Helsinki
University of Helsinki, Clinicum
Date: 2017-08-25
Language: eng
Number of pages: 15
Belongs to series: PLoS One
ISSN: 1932-6203
URI: http://hdl.handle.net/10138/224337
Abstract: Objective YKL-40, a chitinase-like glycoprotein associated with inflammation and tissue remodeling, is produced by joint tissues and recognized as a candidate auto-antigen in rheumatoid arthritis (RA). In the present study, we investigated YKL-40 as a potential biomarker of disease activity in patients with early RA at baseline and during intensive treatment aiming for early remission. Methods Ninety-nine patients with early DMARD-naive RA participated in the NEO-RACo study. For the first four weeks, the patients were treated with the combination of sulphasalazine, methotrexate, hydroxychloroquine and low dose prednisolone (FIN-RACo DMARD combination), and subsequently randomized to receive placebo or infliximab added on the treatment for further 22 weeks. Disease activity was evaluated using the 28-joint disease activity score and plasma YKL-40 concentrations were measured by immunoassay. Results At the baseline, plasma YKL-40 concentration was 57 +/- 37 ( mean +/- SD) ng/ml. YKL-40 was significantly associated with the disease activity score, interleukin-6 and erythrocyte sedimentation rate both at the baseline and during the 26 weeks' treatment. The csDMARD combination decreased YKL-40 levels already during the first four weeks of treatment, and there was no further reduction when the tumour necrosis factor-alpha antagonist infliximab was added on the combination treatment. Conclusions High YKL-40 levels were found to be associated with disease activity in early DMARD-naive RA and during intensive treat-to-target therapy. The present results suggest YKL-40 as a useful biomarker of disease activity in RA to be used to steer treatment towards remission.
Subject: HUMAN CARTILAGE GLYCOPROTEIN-39
SERUM YKL-40
RADIOGRAPHIC PROGRESSION
COMBINATION THERAPY
PERIPHERAL-BLOOD
ACTIVITY SCORES
FOLLOW-UP
MHC CLASS
JOINT
INFLAMMATION
3121 Internal medicine
3111 Biomedicine
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
file.pdf 2.910Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record